FIG Therapeutics develops intratumoral gene‑therapy that turns solid tumors into “bioreactor” factories for immunotherapy. A single non‑replicating viral injection reprograms the tumor to secrete more than ten coordinated immunotherapy payloads in stages, achieving over 700‑fold higher protein secretion and 100–3,000× potency versus standard agents, while avoiding systemic toxicity. The platform is initially targeting high‑risk prostate cancer to generate a systemic anti‑tumor response from a local treatment.
Funding
Funding not disclosed
Founders
Product
Problem
Cold tumors evade immune detection through multiple concurrent mechanisms—including suppressive immune cells, inhibitory signaling pathways, and physical barriers—making single-agent systemic immunotherapies ineffective and often toxic.
Solution
FIG Therapeutics’ Symphony™ platform delivers a single intratumoral injection of a non‑replicating viral vector engineered with a high‑output signal peptide. This reprograms tumor cells into bioreactors that secrete more than ten immunotherapy payloads in staged waves, targeting key escape pathways such as CTLA‑4, PD‑L1, CD40, and IL‑12. The engineered signal peptide boosts protein secretion by over 700‑fold, achieving 100–3,000× potency versus clinical comparators while avoiding systemic exposure. Localized, multimodal delivery addresses cellular, molecular, and physical immunosuppressive factors simultaneously, generating a systemic anti‑tumor response without the toxicity of systemic combinations.
Target Audience
Primary customers are oncology clinicians and health systems treating high‑risk localized and metastatic prostate cancer, with expansion potential to any solid tumor accessible by needle injection.
Features
- Non‑replicating viral vector delivering a single drug product for one‑time intratumoral injection
- Engineered signal peptide (FIG SP3) that increases tumor protein secretion >700‑fold
- Staged release of 10+ coordinated immunotherapy agents (anti‑CTLA‑4, anti‑PD‑L1, CD40 agonist, IL‑12, etc.) in multiple waves
- Potency 100–3,000× higher than standard clinical comparators for each payload
- Designed to overcome cellular (M2 macrophages, MDSCs, Tregs), molecular (TGF‑β, PD‑L1, VEGF), and physical (dense ECM, hypoxia) immune‑evasion mechanisms
- Enables systemic anti‑tumor immunity from a localized treatment, reducing systemic toxicity